Tracking tumor resistance in metastatic colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies how colorectal cancer that has spread becomes resistant to treatment. By taking biopsies over time, researchers hope to find new ways to target the cancer and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer (cancer of the colon or rectum).
- Your tumor must not be MSI-H (a specific genetic marker) — your doctor can check this.
- You must have a tumor that can be biopsied (a small sample taken for testing).
- You must be 18 years or older.
- You should be able to do light activities (ECOG 0-2).
- You must not have had both oxaliplatin and irinotecan (two chemotherapy drugs) for metastatic cancer.
- Your cancer must have progressed (grown or spread) on your most recent treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This study looks at why some people with a specific type of colorectal cancer (BRAF V600E-mutated) stop responding to targeted drugs over time. Researchers will take small tissue samples before and during your treatment with anti-EGFR antibody and BRAF inhibitor to understand resistance and help improve future treatments.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This Phase 2 trial tests a chemotherapy combination (liposomal irinotecan), along with TAS-102 and bevacizumab, in people with metastatic colon cancer. It may help if your tumor has mismatch repair–proficient features and you’ve already tried standard colon cancer drugs.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.